Beam Therapeutics Inc. (BEAM)
undefined
undefined%
At close: undefined
28.00
0.32%
After-hours Dec 13, 2024, 04:29 PM EST

Company Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.

The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.

The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel.

It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc.

The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc.
Beam Therapeutics Inc. logo
Country United States
IPO Date Feb 6, 2020
Industry Biotechnology
Sector Healthcare
Employees 472
CEO John M. Evans M.B.A.

Contact Details

Address:
238 Main Street
Cambridge, Massachusetts
United States
Website https://www.beamtx.com

Stock Details

Ticker Symbol BEAM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001745999
CUSIP Number 07373V105
ISIN Number US07373V1052
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
John M. Evans M.B.A. Chief Executive Officer & Director
Dr. Christine P. Bellon J.D., Ph.D. Senior Vice President, Chief Legal Officer & Corporate Secretary
Dr. Manmohan Singh Ph.D. Chief Technology Officer
Bethany J. Cavanagh Senior Vice President of Finance & Treasurer
Dr. Amy Simon M.D. Chief Medical Officer
Dr. David R. Liu Ph.D. Co-Founder
Dr. Feng Zhang Ph.D. Co-Founder
Dr. Giuseppe Ciaramella Ph.D. President
Dr. Gopi Shanker Ph.D. Chief Scientific Officer
Dr. J. Keith Joung M.D., Ph.D. Co-Founder

Latest SEC Filings

Date Type Title
Dec 09, 2024 8-K Current Report
Dec 06, 2024 8-K Current Report
Dec 04, 2024 4 Filing
Dec 04, 2024 3 Filing
Dec 04, 2024 8-K Current Report
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 08, 2024 4 Filing
Nov 08, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 07, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 05, 2024 10-Q Quarterly Report